Yüklüyor......
Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
BACKGROUND: Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documented in the...
Kaydedildi:
| Yayımlandı: | Clin Transl Allergy |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5870812/ https://ncbi.nlm.nih.gov/pubmed/29599966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-018-0195-x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|